Pharma
Take The Lead

October 2, 2018

Regional Administrator
US Nuclear Regulatory Commission
Region IV
Division of Nuclear Materials Safety
1600 East Lamar Boulevard
Arlington, TX 76011-4511

Subject: Response to Inspection of Pharmalogic, Wyoming for license # 49-27629-01MD

Dear Sir or Madam,

This letter is to serve as a response to the NRC's inspection of Pharmalogic WY, Inc, on September 19th, 2018.

It was noted in the inspection that Air monitoring of I-131 emissions has not been performed since 2012 because Wyoming stopped compounding I 131 capsules in 2012. We hold ordered I131 capsules in the fume hood, in their manufacturer original, unopened, sealed container, prior to dispensing the next day. It was the thought of the pharmacy that, since no I-131 was being compounded on site, and no manufacturer vials were being exposed to open air, that effluence monitoring was not required. Therefore, any volatilization from the capsule remained inside the sealed, unopened container.

As of the day of the inspection, the fume hood has been continually running. New filters were ordered, and upon receipt, emission monitoring will begin.

Corrective steps that will be fully implemented by 10/15/2018 will be full I-131 emission monitoring per attachment 6.4 of our license application. Additionally, we will demonstrate by 12/31/2018, that any I-131 emissions from the pharmacy since 2012 were below the licensed limits.

If you have any questions, please do not hesitate to reach out to me at 703.851.3025.

Thank you,

Reid Gadziala, PharmD., BCNP, MBA
Pharmalogic Holdings Corp.
Director, Quality and Regulatory Affairs
rgadziala@pharmalogic.info
703.851.3025

ORIGINAL